MARKET

NNVC

NNVC

NANOVIRICIDES
AMEX

Real-time Quotes | Nasdaq Last Sale

4.780
+0.950
+24.80%
Opening 13:51 01/22 EST
OPEN
3.830
PREV CLOSE
3.830
HIGH
4.780
LOW
3.581
VOLUME
1.58M
TURNOVER
--
52 WEEK HIGH
19.20
52 WEEK LOW
2.850
MARKET CAP
50.98M
P/E (TTM)
-2.1852
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Corona Virus Treatment Market Size, Share Global Industry Current Trends, Top Companies, Application, Growth Factors, Development and Forecast to 2025 Research Report
Jan 21, 2021 (The Expresswire) -- Global Corona Virus Treatment Market Research Report focuses on market size, status and forecast 2021-2025, along with this...
The Express Wire · 1d ago
Global Viral Conjunctivitis Pipeline Drugs Market 2021: Boosting the growth Worldwide: Market dynamics and trends, efficiencies Forecast 2025
Jan 12, 2021 (The Expresswire) -- Global “Viral Conjunctivitis Pipeline Drugs Market” is segmented by region, players, by Type, and by Application. Players,...
The Express Wire · 01/12 08:02
Viral Conjunctivitis Pipeline Drugs Market Peak Countries in the world 2021 Research Reports, Industry Size, In-Depth Qualitative Insights, Explosive Growth Opportunity, Regional Analysis
Jan 11, 2021 (The Expresswire) -- “Final Report will add the analysis of the impact of COVID-19 on the Viral Conjunctivitis Pipeline Drugs industry.” Global...
The Express Wire · 01/11 05:05
Global Market Outlook for the Coronavirus Vaccine Market to 2027, Featuring Moderna Inc, GeoVax, Inovio Pharmaceuticals and more
, /PRNewswire/ -- The report has been added to offering.
PR Newswire - PRF · 12/17/2020 12:15
NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA
SHELTON, CT / ACCESSWIRE / November 19, 2020 / NanoViricides, Inc. (NYSE Amer.:) (the "Company"), a leader in developing novel nanomedicines to treat viral diseases, announced today that Mr. Brian Zucker, CPA, has joined the Company's Board of Directors, effective November 13, 2020, as an independent director. He was also appointed as a member of the Board's Audit Committee, Nomination Committee and Compensation Committee.
ACCESSWIRE · 11/19/2020 11:21
NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA
SHELTON, CT / ACCESSWIRE / November 19, 2020 / NanoViricides, Inc. (NYSE Amer.:) (the "Company"), a leader in developing novel nanomedicines to treat viral diseases, announced today that Mr. Brian Zucker, CPA, has joined the Company's Board of Directors, e...
ACCESSWIRE · 11/19/2020 11:21
NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA
SHELTON, CT / ACCESSWIRE / November 19, 2020 / NanoViricides, Inc.
ACCESSWIRE · 11/19/2020 11:20
NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA
SHELTON, CT / ACCESSWIRE / November 19, 2020 / NanoViricides, Inc.
ACCESSWIRE · 11/19/2020 11:20
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NNVC. Analyze the recent business situations of NANOVIRICIDES through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NNVC stock price target is 14.50 with a high estimate of 14.50 and a low estimate of 14.50.
EPS
Institutional Holdings
Institutions: 38
Institutional Holdings: 3.05M
% Owned: 28.56%
Shares Outstanding: 10.66M
TypeInstitutionsShares
Increased
3
85.77K
New
2
25.06K
Decreased
6
173.75K
Sold Out
4
1.42M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/President/Executive Director
Anil Diwan
Chief Financial Officer
Meeta Vyas
Independent Director
Stanley Glick
Independent Director
Makarand Jawadekar
Independent Director
Theodore Rokita
Independent Director
Brian Zucker
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NNVC
NanoViricides, Inc. is a nano-biopharmaceutical research and development company. The Company is engaged the discovery, development, and commercialization of drugs to combat viral infections using its nanomedicines technology. The Company provides nanoviricide technology, which enables direct attacks at multiple points on a virus particle. The nanoviricide technology is engaged in both attacking extracellular virus thereby breaking the reinfection cycle, and simultaneously disrupting intracellular production of the virus, thereby enabling complete control of a virus infection. The nanoviricide technology also simultaneously enables attacking the intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The Company’s lead product candidate is NV-HHV-101 in the HerpeCide program, as a skin cream for the treatment of shingles rash.
More

Webull offers kinds of NanoViricides Inc stock information, including AMEX:NNVC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NNVC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NNVC stock methods without spending real money on the virtual paper trading platform.